Emerging biotechnology company Egle Therapeutics has achieved the first milestone in its strategic research alliance with Japan's Takeda Pharmaceutical Company Limited (TYO:4502), the company announced on Thursday.

Under the research alliance, which was announced in June 2020, Egle will validate novel tumour-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.

Egle has leveraged its bioinformatic and translational capabilities to successfully identify targets that will now be pursued through the alliance. Upon achievement of the target identification, Egle will receive an undisclosed R&D milestone payment and investment from Takeda.